CA2353776A1 - Composition and method for regulation of body weight and associated conditions - Google Patents

Composition and method for regulation of body weight and associated conditions Download PDF

Info

Publication number
CA2353776A1
CA2353776A1 CA002353776A CA2353776A CA2353776A1 CA 2353776 A1 CA2353776 A1 CA 2353776A1 CA 002353776 A CA002353776 A CA 002353776A CA 2353776 A CA2353776 A CA 2353776A CA 2353776 A1 CA2353776 A1 CA 2353776A1
Authority
CA
Canada
Prior art keywords
animal
compound
pomc
body weight
melanocortin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002353776A
Other languages
English (en)
French (fr)
Inventor
Miles B. Brennan
Ute Hochgeschwender
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roosevelt Eleanor Institute for Cancer Research Inc
Oklahoma Medical Research Foundation
Original Assignee
Eleanor Roosevelt Institute
Miles B. Brennan
Ute Hochgeschwender
Oklahoma Medical Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/374,827 external-priority patent/US6603058B1/en
Application filed by Eleanor Roosevelt Institute, Miles B. Brennan, Ute Hochgeschwender, Oklahoma Medical Research Foundation filed Critical Eleanor Roosevelt Institute
Publication of CA2353776A1 publication Critical patent/CA2353776A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
CA002353776A 1998-12-09 1999-12-09 Composition and method for regulation of body weight and associated conditions Abandoned CA2353776A1 (en)

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US11158198P 1998-12-09 1998-12-09
US60/111,581 1998-12-09
US14630399P 1999-07-29 1999-07-29
US14630499P 1999-07-29 1999-07-29
US14630699P 1999-07-29 1999-07-29
US14630599P 1999-07-29 1999-07-29
US14630099P 1999-07-29 1999-07-29
US14630199P 1999-07-29 1999-07-29
US14629999P 1999-07-29 1999-07-29
US14630299P 1999-07-29 1999-07-29
US60/146,304 1999-07-29
US60/146,301 1999-07-29
US60/146,305 1999-07-29
US60/146,300 1999-07-29
US60/146,299 1999-07-29
US60/146,303 1999-07-29
US60/146,302 1999-07-29
US60/146,306 1999-07-29
US09/374,827 US6603058B1 (en) 1998-12-09 1999-08-12 Non-human animal model for obesity and uses thereof
US09/374,827 1999-08-12
PCT/US1999/029337 WO2000033658A1 (en) 1998-12-09 1999-12-09 Composition and method for regulation of body weight and associated conditions

Publications (1)

Publication Number Publication Date
CA2353776A1 true CA2353776A1 (en) 2000-06-15

Family

ID=27581011

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002353776A Abandoned CA2353776A1 (en) 1998-12-09 1999-12-09 Composition and method for regulation of body weight and associated conditions

Country Status (6)

Country Link
EP (1) EP1137340A4 (es)
JP (1) JP2003520015A (es)
AU (1) AU3117600A (es)
CA (1) CA2353776A1 (es)
MX (1) MXPA01005818A (es)
WO (1) WO2000033658A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002064091A2 (en) 2001-02-13 2002-08-22 Palatin Technologies, Inc. Melanocortin metallopeptides for treatment of sexual dysfunction
JP2004509065A (ja) * 2000-04-28 2004-03-25 ゼンジェン　インコーポレイテッド α−ＭＳＨおよびその誘導体を用いる遺伝子治療システムおよび方法
JP2004506417A (ja) 2000-07-14 2004-03-04 ザイコス　インク． α−ＭＳＨ関連化合物および使用方法
EP1322954A4 (en) * 2000-09-13 2005-08-03 Eleanor Roosevelt Inst METHOD FOR TREATING INSULIN RESISTANCE IN OVERWEIGHT AND DIABETES
US20060293223A1 (en) * 2003-06-19 2006-12-28 Eli Lilly And Company Patent Division Uses of melanocortin-3 receptor (mc3r) agonist peptides
US20070105759A1 (en) * 2003-06-19 2007-05-10 Eli Lilly And Company Melanocortin receptor 4 (mc4) agonists and their uses
FR2857873B1 (fr) * 2003-07-21 2006-02-24 Courtage Et De Diffusion Codif Procede et produit cosmetique destines a limiter la croissance des tissus adipeux
WO2005102377A1 (en) * 2004-03-29 2005-11-03 Eli Lilly And Company Uses of melanocortin-4 receptor (mc4r) agonist peptides administered by continuous infusion
DE602005026380D1 (de) * 2004-04-08 2011-03-31 Astellas Pharma Inc Verbindung ws727713
WO2005118573A1 (en) 2004-05-28 2005-12-15 Smithkline Beecham Corporation Novel diazepine compounds as ligands of the melanocortin 1 and/or 4 receptors
US7169773B2 (en) 2004-07-01 2007-01-30 Smithkline Beecham Corporation Compounds
US7910101B2 (en) 2004-10-25 2011-03-22 Centocor, Inc. Melanocortin receptor binding mimetibodies, compositions, methods and uses
ME01234B (me) * 2004-10-25 2013-06-20 Centocor Inc Mimetička tijela koja vezuju receptore melanokortina, smjese, postupci i upotrebe
WO2006073771A2 (en) * 2005-01-05 2006-07-13 Eli Lilly And Company Polyethylene glycol linked mc4r or mc3r agonist peptides
US8716220B2 (en) 2005-09-07 2014-05-06 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta
US7790671B2 (en) * 2005-10-07 2010-09-07 Codman & Shurtleff, Inc. Implantable pump for protein delivery for obesity control by drug infusion into the brain
EP2326339A4 (en) 2008-05-21 2012-06-20 Neurotez Inc METHOD FOR TREATING PROGRESSIVE COGNITIVE DISORDER IN CONNECTION WITH NEUROFIBRILLARY TANGLES

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100048A (en) * 1992-04-10 2000-08-08 Oregon Health Sciences University Methods and reagents for discovering and using mammalian melanocortin receptor agonists and antagonists to modulate feeding behavior in animals
US5932779A (en) * 1996-06-10 1999-08-03 Millennium Pharmaceuticals, Inc. Screening methods for compounds useful in the regulation of body weight

Also Published As

Publication number Publication date
EP1137340A1 (en) 2001-10-04
AU3117600A (en) 2000-06-26
EP1137340A4 (en) 2005-12-21
JP2003520015A (ja) 2003-07-02
MXPA01005818A (es) 2003-07-21
WO2000033658A1 (en) 2000-06-15

Similar Documents

Publication Publication Date Title
US20060063708A1 (en) Composition and method for regulation of body weight and associated conditions
US20030144174A1 (en) Methods for identifying compounds useful for the regulation of body weight and associated conditions
Tao The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology
Tschöp et al. Rodent obesity models: an overview
US7186694B2 (en) Leptin-related peptides
CA2353776A1 (en) Composition and method for regulation of body weight and associated conditions
US7790683B2 (en) Leptin-related peptides
US6689938B2 (en) Method for treatment of insulin resistance in obesity and diabetes
WO2004039832A2 (en) Leptin-related peptides
CA2475273A1 (en) Modified pituitary gland development in offspring from expectant mother animals treated with growth hormone releasing hormone therapy
Tao Mutations in melanocortin-4 receptor: From fish to men
Hsiung et al. A novel and selective β-melanocyte-stimulating hormone-derived peptide agonist for melanocortin 4 receptor potently decreased food intake and body weight gain in diet-induced obese rats
CN101505786A (zh) 涉及能量内稳态的新肽
US6603058B1 (en) Non-human animal model for obesity and uses thereof
US7084242B2 (en) DNA molecule encoding a mutant prepro-neuropeptide Y, a mutant signal peptide, and uses thereof
Fang et al. Development of a transgenic mouse that overexpresses a novel product of the growth hormone-releasing hormone gene
WO2001072119A2 (en) Non-human animal model for growth deficiency and information processing or cognitive function defects and use thereof
US20120079613A1 (en) Homeobox Transcription Factor BSX and Uses Thereof for Treating Diseases, in Particular Obesity
Ersoy Deciphering the melanocortin system: Three distinct approaches
BRPI9508596B1 (pt) polipeptídeos de obesidade (ob), composição compreendendo os mesmos, bem como vetores para expressão dos referidos polipeptídeos

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead